日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Correction to: Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review

更正：SDZ-ADL（一种阿达木单抗生物类似药）在未接受过生物制剂治疗和转换治疗的免疫介导炎症性疾病患者中的疗效、安全性和免疫原性：文献综述

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-025-03181-z
Wiland, Piotr; Both, Charlotte; Gaylis, Norman B; Cohen, Russell D; Halfvarson, Jonas; Lemke, Lena; von Richter, Oliver; Blauvelt, Andrew
炎症/感染
炎症
免疫/内分泌
发表日期：2025
文献求助 收藏

Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review

SDZ-ADL（一种阿达木单抗生物类似药）在既往未接受过生物制剂治疗和转换治疗的免疫介导炎症性疾病患者中的疗效、安全性和免疫原性：文献综述

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-024-03098-z
Wiland, Piotr; Both, Charlotte; Gaylis, Norman B; Cohen, Russell D; Halfvarson, Jonas; Lemke, Lena; von Richter, Oliver; Blauvelt, Andrew
炎症/感染
炎症
免疫/内分泌
发表日期：2025
文献求助 收藏

Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab

将生物类似药模式引入神经病学领域：首个生物类似药那他珠单抗的全部证据

期刊:BioDrugs
影响因子:6.9
doi:10.1007/s40259-024-00671-4
Selmaj, Krzysztof; Roth, Karsten; Höfler, Josef; Vitzithum, Klaus; Derlacz, Rafał; von Richter, Oliver; Hornuss, Cyrill; Poetzl, Johann; Singer, Barry; Jacobs, Laura
发表日期：2024
文献求助 收藏

Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile

纳他珠单抗生物类似药与其参考药物的免疫原性比较评估：匹配的免疫原性谱

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2024.1414304
Chamberlain, Paul; Hemmer, Bernhard; Höfler, Josef; Wessels, Hendrik; von Richter, Oliver; Hornuss, Cyrill; Poetzl, Johann; Roth, Karsten
免疫/内分泌
发表日期：2024
文献求助 收藏

'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar

在已获批准的阿达木单抗生物类似药GP2017的研发过程中采用“证据总体性”方法

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-024-02809-w
Gaylis, Norman; Both, Charlotte; Lemke, Lena; von Richter, Oliver; Yamauchi, Paul
发表日期：2024
文献求助 收藏

Stepping up to the thermogradient plate: a data framework for predicting seed germination under climate change

迈向热梯度平台：气候变化下种子萌发预测的数据框架

期刊:Annals of Botany
影响因子:3.6
doi:10.1093/aob/mcac026
Collette, Justin C; Sommerville, Karen D; Lyons, Mitchell B; Offord, Catherine A; Errington, Graeme; Newby, Zoe-Joy; von Richter, Lotte; Emery, Nathan J
发表日期：2022
文献求助 收藏

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial

英夫利昔单抗 (IFX) 生物类似药 PF-06438179/GP1111 在类风湿性关节炎患者中长期疗效、安全性和免疫原性评估（从参考 IFX 转换或继续接受生物类似药治疗）：一项随机、双盲、III 期试验的第 54-78 周数据

期刊:BioDrugs
影响因子:6.9
doi:10.1007/s40259-019-00403-z
Cohen, Stanley B; Radominski, Sebastiao C; Kameda, Hideto; Kivitz, Alan J; Tee, Michael; Cronenberger, Carol; Zhang, Min; Hackley, Sarah; Rehman, Muhammad I; von Richter, Oliver; Alten, Rieke
关节炎
免疫/内分泌
发表日期：2020
文献求助 收藏

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54

一项随机、双盲、III期研究比较了英夫利昔单抗生物类似药PF-06438179/GP1111与参考英夫利昔单抗：从第30周到第54周的疗效、安全性和免疫原性。

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2018-000876
Alten, Rieke; Batko, Bogdan; Hala, Tomas; Kameda, Hideto; Radominski, Sebastiao C; Tseluyko, Vira; Babic, Goran; Cronenberger, Carol; Hackley, Sarah; Rehman, Muhammad; von Richter, Oliver; Zhang, Min; Cohen, Stanley
免疫/内分泌
发表日期：2019
文献求助 收藏

A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide

一种评估细胞毒性前药依沃福酰胺的细胞色素P450介导的药物相互作用潜力的新型PBPK模型方法

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12360
Lüpfert, Christian; Dyroff, Martin; von Richter, Oliver; Gallemann, Dieter; El Bawab, Samer; Dolgos, Hugues; Jung, Don; Hecht, Stefan; Johne, Andreas
细胞生物学
毒理研究
发表日期：2018
文献求助 收藏

TAM receptors Tyro3 and Mer as novel targets in colorectal cancer

TAM受体Tyro3和Mer作为结直肠癌的新靶点

期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.10889
Schmitz, Robin; Valls, Aida Freire; Yerbes, Rosario; von Richter, Sophie; Kahlert, Christoph; Loges, Sonja; Weitz, Jürgen; Schneider, Martin; Ruiz de Almodovar, Carmen; Ulrich, Alexis; Schmidt, Thomas
信号转导
Mer
肿瘤
肠癌
肿瘤免疫
发表日期：2016
文献求助 收藏